FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3009091013> ?p ?o ?g. }

• W3009091013 endingPage "705" @default.
• W3009091013 startingPage "693" @default.
• W3009091013 abstract "To compare a range of clinical outcome variables (intraocular pressure, glaucoma medications, visual acuity, and complications) between two Ahmed glaucoma valve (AGV) models (S2 and FP7).This was a prospective and randomized clinical trial. Fifty-six patients with refractory glaucoma were randomly assigned to be implanted with either a polypropylene (S2) or silicone (FP7) Ahmed glaucoma valve. The primary outcome measure was a surgical success, defined as an IOP ≤ 16 mm Hg (without medication), and guarded success, defined as a controlled IOP ≤ 16 mmHg (with medication). Failure was defined as when the IOP lay outside of the successful range on two consecutive visits (>16 mmHg, despite medication).Mean follow-up period was 398.42 ± 12.34 days (range, 380-420 days) for the S2 group and 401.75 ± 9.78 days (range, 385-420 days) for the FP7 group; these values were not significantly different (P = 0.27). After 12 months of follow-up, the baseline IOP (45.42 mmHg) fell significantly to 16.14 mmHg in the S2 group (p < 0.000); there was also a significant reduction in IOP in the FP7 group (from 44.17 mmHg to 15.18 mmHg in FP7 group, p < 0.000). At the last follow-up examination, the mean IOP in the S2 group was 16.14 ± 3.18 mmHg, while that of the FP7 group was 15.18 ± 2.75 mmHg; there was no significant difference between the two groups with this respect (p = 0.23). The mean number of medications used by patients in the S2 and FP7 groups was 2.92 ± 1.27 and 2.75 ± 1.43, respectively; there was no significant difference between the two groups with this respect (p = 0.32). There was no significant difference between the FP7 and S2 groups with regard to their relative success rate (17.89% [5/28] versus 10.7% [3/28], respectively; p = 0.38).Our data show that the S2 and FP7 models of AGV were both effective in lowering IOP and reducing the need for glaucoma medications. Although these two AGV models had similar dimensions, they were constructed from different materials. However, there were no significant clinical differences between the S2 and FP7 AGV groups after 12 months of follow-up. Furthermore, our data indicate that bleb encapsulation was the primary factor responsible for failure rate and the need for glaucoma medication in both the S2 and FP7 groups. Our analysis further indicates that the S2 and FP7 Ahmed valves are associated with a high risk of failure when considered as a first-line therapy for cases experiencing trabeculectomy.NCT04214847." @default.
• W3009091013 created "2020-03-13" @default.
• W3009091013 creator A5011809079 @default.
• W3009091013 creator A5045866804 @default.
• W3009091013 date "2020-03-01" @default.
• W3009091013 modified "2023-09-24" @default.
• W3009091013 title "<p>A One-Year Follow-Up of Two Ahmed Glaucoma Valve Models (S2 and FP7) for Refractory Glaucoma: A Prospective Randomized Trial</p>" @default.
• W3009091013 cites W1830315438 @default.
• W3009091013 cites W1898293549 @default.
• W3009091013 cites W1968108770 @default.
• W3009091013 cites W1968796769 @default.
• W3009091013 cites W1969673336 @default.
• W3009091013 cites W1971856941 @default.
• W3009091013 cites W1979568835 @default.
• W3009091013 cites W1990333822 @default.
• W3009091013 cites W2001982613 @default.
• W3009091013 cites W2004363127 @default.
• W3009091013 cites W2014759738 @default.
• W3009091013 cites W2016721093 @default.
• W3009091013 cites W2019469051 @default.
• W3009091013 cites W2022186868 @default.
• W3009091013 cites W2022264363 @default.
• W3009091013 cites W2025321240 @default.
• W3009091013 cites W2031128696 @default.
• W3009091013 cites W203882112 @default.
• W3009091013 cites W2043303292 @default.
• W3009091013 cites W2047382931 @default.
• W3009091013 cites W2066907707 @default.
• W3009091013 cites W2067267514 @default.
• W3009091013 cites W2083411264 @default.
• W3009091013 cites W2094790744 @default.
• W3009091013 cites W2102457367 @default.
• W3009091013 cites W2105757324 @default.
• W3009091013 cites W2106413124 @default.
• W3009091013 cites W2108135200 @default.
• W3009091013 cites W2141298988 @default.
• W3009091013 cites W2144539348 @default.
• W3009091013 cites W2152874576 @default.
• W3009091013 cites W2163716576 @default.
• W3009091013 cites W2167366097 @default.
• W3009091013 cites W272617585 @default.
• W3009091013 cites W2787910023 @default.
• W3009091013 cites W3008136668 @default.
• W3009091013 cites W371399941 @default.
• W3009091013 cites W81263109 @default.
• W3009091013 doi "https://doi.org/10.2147/opth.s224653" @default.
• W3009091013 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7061428" @default.
• W3009091013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32184556" @default.
• W3009091013 hasPublicationYear "2020" @default.
• W3009091013 type Work @default.
• W3009091013 sameAs 3009091013 @default.
• W3009091013 citedByCount "3" @default.
• W3009091013 countsByYear W30090910132022 @default.
• W3009091013 countsByYear W30090910132023 @default.
• W3009091013 crossrefType "journal-article" @default.
• W3009091013 hasAuthorship W3009091013A5011809079 @default.
• W3009091013 hasAuthorship W3009091013A5045866804 @default.
• W3009091013 hasBestOaLocation W30090910131 @default.
• W3009091013 hasConcept C118487528 @default.
• W3009091013 hasConcept C121332964 @default.
• W3009091013 hasConcept C141071460 @default.
• W3009091013 hasConcept C142424586 @default.
• W3009091013 hasConcept C168563851 @default.
• W3009091013 hasConcept C188816634 @default.
• W3009091013 hasConcept C2776508836 @default.
• W3009091013 hasConcept C2778257484 @default.
• W3009091013 hasConcept C2778527774 @default.
• W3009091013 hasConcept C2780819948 @default.
• W3009091013 hasConcept C2781092963 @default.
• W3009091013 hasConcept C71924100 @default.
• W3009091013 hasConcept C87355193 @default.
• W3009091013 hasConceptScore W3009091013C118487528 @default.
• W3009091013 hasConceptScore W3009091013C121332964 @default.
• W3009091013 hasConceptScore W3009091013C141071460 @default.
• W3009091013 hasConceptScore W3009091013C142424586 @default.
• W3009091013 hasConceptScore W3009091013C168563851 @default.
• W3009091013 hasConceptScore W3009091013C188816634 @default.
• W3009091013 hasConceptScore W3009091013C2776508836 @default.
• W3009091013 hasConceptScore W3009091013C2778257484 @default.
• W3009091013 hasConceptScore W3009091013C2778527774 @default.
• W3009091013 hasConceptScore W3009091013C2780819948 @default.
• W3009091013 hasConceptScore W3009091013C2781092963 @default.
• W3009091013 hasConceptScore W3009091013C71924100 @default.
• W3009091013 hasConceptScore W3009091013C87355193 @default.
• W3009091013 hasLocation W30090910131 @default.
• W3009091013 hasLocation W30090910132 @default.
• W3009091013 hasLocation W30090910133 @default.
• W3009091013 hasLocation W30090910134 @default.
• W3009091013 hasOpenAccess W3009091013 @default.
• W3009091013 hasPrimaryLocation W30090910131 @default.
• W3009091013 hasRelatedWork W1186832327 @default.
• W3009091013 hasRelatedWork W2007355088 @default.
• W3009091013 hasRelatedWork W2394464390 @default.
• W3009091013 hasRelatedWork W2939918051 @default.
• W3009091013 hasRelatedWork W2967025347 @default.
• W3009091013 hasRelatedWork W3029233731 @default.
• W3009091013 hasRelatedWork W3147348768 @default.
• W3009091013 hasRelatedWork W4254756478 @default.

• next